Oral leukoplakia: To treat or not to treat
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Oral leukoplakia : To treat or not to treat. / Holmstrup, Palle; Dabelsteen, Erik.
In: Oral Diseases, Vol. 22, No. 6, 20.01.2016, p. 494-497.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Oral leukoplakia
T2 - To treat or not to treat
AU - Holmstrup, Palle
AU - Dabelsteen, Erik
N1 - This article is protected by copyright. All rights reserved.
PY - 2016/1/20
Y1 - 2016/1/20
N2 - The idea of identifying oral lesions with a precancerous nature, i.e. in the sense of pertaining to a pathologic process with an increased risk for future malignant development, of course is to prevent frank malignancy to occur in the affected area. The most common oral lesion with a precancerous nature is oral leukoplakia, and for decades it has been discussed how to treat these lesions. Various treatment modalities, such as systemic therapies and surgical removal, have been suggested. The systemic therapies tested so far include retinoids, extracts of green tea, inhibitors of cyclooxygenase-2 and of epidermal growth factor, and peroxisome proliferator activated receptor-γ agonists (William, 2012), but there is no generally approved standard systemic therapy regimen so far (William, 2012). This article is protected by copyright. All rights reserved.
AB - The idea of identifying oral lesions with a precancerous nature, i.e. in the sense of pertaining to a pathologic process with an increased risk for future malignant development, of course is to prevent frank malignancy to occur in the affected area. The most common oral lesion with a precancerous nature is oral leukoplakia, and for decades it has been discussed how to treat these lesions. Various treatment modalities, such as systemic therapies and surgical removal, have been suggested. The systemic therapies tested so far include retinoids, extracts of green tea, inhibitors of cyclooxygenase-2 and of epidermal growth factor, and peroxisome proliferator activated receptor-γ agonists (William, 2012), but there is no generally approved standard systemic therapy regimen so far (William, 2012). This article is protected by copyright. All rights reserved.
U2 - 10.1111/odi.12443
DO - 10.1111/odi.12443
M3 - Journal article
C2 - 26785709
VL - 22
SP - 494
EP - 497
JO - Oral Diseases
JF - Oral Diseases
SN - 1354-523X
IS - 6
ER -
ID: 157242098